Netscientific Share Discussion Threads

[loafofbread] 26/10/2023 19:23

Q Bot interview on Proactive if anyone is interested.

[blakieboy7] 24/10/2023 08:55

A sea of red today

[loafofbread] 17/10/2023 22:56

Some decent news on the SageTech website.

CE mark and first product sales.

[blakieboy7] 11/10/2023 13:35

PDS Biotech Announces Interim Safety and Immune Response Data from Phase 1/2 Clinical Trial Evaluating Novel Antibody Drug Conjugate PDS0301 Combined with Docetaxel to Treat Metastatic Prostate CancerInterim data highlights to be presented at Cytokines 2023 include:•Decrease in PSA levels was seen in all patients at all three tested doses of PDS0301 and ranged from -4% to -100%.•All doses of the combination were well-tolerated with one patient experiencing Grade 4 neutropenia.

[blakieboy7] 06/10/2023 13:28

PDSB up over 5% pre market

[blakieboy7] 06/10/2023 08:07

PDSB starting to recover now, up over 8% yesterday

[kingston78] 03/10/2023 16:56

The attraction of NSCI to me is summarised as follows:
1) Incremental value of its investee companies over time;
2) Mainly external funding by third parties to those investee companies, at higher valuation, conserving cash at NSCI group level and at the same time enhancing value attributing to NSCI;
3) Partial and potentially full exits from investee companies, providing working capital to NSCI and crystallising profits in cash;
4) Certain investments are valued at zero or at a low value, so there is nothing or little to lose;
5) If a blockbuster event occurs to PDS the value attributing to NSCI will be enormous; and
6) Its corporate advisory subsidiary will bring in wider contacts and further investment opportunities that most other companies do not have, whilst earning fees performing its work.

[blakieboy7] 03/10/2023 16:40

The PDSB share price makes absolutely no sense to me!!

[1gw] 03/10/2023 16:37

Perhaps a week to be grateful that NSCI doesn't follow the PDSB shareprice too closely. My assumption was that on good data (which these 2 releases appear to be at a quick reading) and a consequent price spike PDSB would be likely to use its shelf registration to sell shares into strength and extend its cash runway, in the process probably limiting the upside in PDSB shareprice. Have they jumped the gun and sold too much too soon? Or has someone been front-running off whatever pre-market strength there was? Or is the market getting nervous about the remaining cash runway vs the funding requirement of these programmes and fearful of larger fund-raising activities?

Any ideas?

[blakieboy7] 03/10/2023 16:16

Director buying

[blakieboy7] 03/10/2023 13:59

https://seekingalpha.com/news/4017521-pds-biotech-stock-gains-data-head-neck-cancer-drug?utm_campaign=twitter_automated&utm_content=news&utm_medium=social&utm_source=twitter_automated

[blakieboy7] 03/10/2023 13:55

PDS Biotechnology announces interim 24-month survival rate of 74% in immune checkpoint inhibitor nave head and neck cancer patients treated with PDS0101 in combination with KEYTRUDA

[blakieboy7] 03/10/2023 12:09

Did anyone watch the webinar?

[loafofbread] 01/10/2023 22:06

Lots of PDSB news this week that should confirm the platform is worth far more than $5 a share.

[paleje] 29/9/2023 09:06

Except....:)

This is a very difficult market by any measure. Good points above though, shouldn't be red.

[blakieboy7] 28/9/2023 21:51

Every time he writes the share price goes up

[sev22] 28/9/2023 15:30

A medtech stock with potential to treble in value.

The investment company’s portfolio is worth 151 per cent more than its market cap and there are hidden assets, too.

September 28, 2023
By Simon Thompson

*First-half pre-tax loss of £1.6mn
*Fair valuation of portfolio down from £41.8mn to £35.5mn (151p)
*Post-period-end disposals improve cash position

Aim-traded investment company Netscientific's (NSCI:60p) headline losses mask an improving trading performance.

More than three-quarters of the flat first-half operating loss of £1.6mn was due to the consolidated losses of two subsidiary companies: Glycotest, a Philadelphia-based liver disease diagnostics company that is commercialising new and unique blood tests for life-threatening liver cancers and fibrosis-cirrhosis; and ProAxsis, a commercial medical technology company with a focus on respiratory diagnostics. Importantly, both companies are being funded by third-party sources as they move towards the commercialisation stage and do not require funding from Netscientific. Excluding Glycotest and ProAxsis, the group operating loss more than halved to £0.3mn.

Moreover, current borrowings of £1.5mn reflect the debt of the two subsidiaries. At a parent level, Netscientific had net cash of £0.3mn on 26 September 2023 and it holds 1.33mn shares worth £5.5mn (23.5p) in PDS Biotechnology Corporation (US: PDSB – $5.10), a $157mn market capitalisation clinical-stage immunotherapy company developing cancer immunotherapies and infectious disease vaccines based on its proprietary Versamune T-cell activating technology platform. The fall in PDS’s share price proved a £9.4mn drag on the portfolio valuation, but this was partly offset by net gains of £3.1mn from three other holdings: Vortex Biotech, Q-Bot and DName-IT.

The group’s 25 per cent stake in Vortex Biotech quadrupled in value to £2.8mn after the company raised £3.2mn in an enterprise investment scheme (EIS) investment round in June 2023. It was led by EMV Capital, the group’s corporate finance boutique. Vortex’s core technology allows for the capture and isolation of high-quality circulating tumour cells from blood samples.

University of Leuven spin-out DName-IT has developed a platform to avoid sample authentication errors and to correct for sample contamination in genetic sequencing laboratory tests. The company operates at the crossroads of the major, growing markets of liquid biopsy, laboratory services, clinical trials and next-generation sequencing. A recent £0.5mn EIS investment round led by EMV Capital increased the valuation of the group’s 36.9 per cent stake from £0.1mn to £1mn.

Netscientifc also booked a £0.3mn gain on its £4.1mn holding in Q-Bot, a London-based robotics and artificial intelligence company that has developed a patented energy-saving robotic system for applying insulation in tight spaces and suspended floors (to reduce heat loss and prevent draughts, damp and mould).

Hidden value in EMV Capital’s carried interests.

The £35.5mn (151p) fair valuation of the portfolio is not only 151 per cent higher than Netscientific’s market capitalisation of £14.1mn, but it places no value on EMV’s capital under advisory (CUA) of £26.1mn, up from £23.5mn at the start of 2023.

EMV’s business model is to syndicate investments between financial and corporate investors, and for its management team to take a strong hands-on role post-investment. Monetisation is through a mixture of corporate finance fees, management and incubation services, and carried interests in the investments it syndicates. True, it is difficult to estimate the current value of these stakes. However, based on an average two times portfolio return on CUA, they could deliver carry returns in excess of £4.5mn (19p) to EMV, or a third of its market capitalisation.

When I suggested buying the shares, at 64p, in my 2023 Bargain Share Portfolio, I highlighted the potential to make profitable exits on the portfolio. This is starting to happen as the group has made £0.8mn of partial exits since July 2023, which provides funding and is supportive of the fair valuations of investee companies. With sum-of-the-parts valuations almost three times the current share price, the shares remain a buy.

[loafofbread] 28/9/2023 07:52

A positive set of results to be sure.

All bits of the portfolio doing well and no more dilution, period.

About time the team bought a few in the market and showed some conviction at this knock down price.

[senttothegallows] 28/9/2023 07:46

NAV 2.5 times share price ++ IMHO

[senttothegallows] 25/9/2023 10:58

Agreed interesting week ahead for NonScientific one of the most undervalued stocks on the market IMHO